Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized

M A Rodger1, S R Kahn, A Cranney

  • 1Ottawa Health Research Institute, University of Ottawa, Ottawa, ON, Canada. mrodger@ohri.ca

Journal of Thrombosis and Haemostasis : JTH
|August 1, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Splanchnic vein thrombosis with and without myeloproliferative neoplasms: a comparative cohort study.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Canadian Surgery Forum.

Canadian journal of surgery. Journal canadien de chirurgie·2022
Same author

MUFFIN-PTS trial, Micronized Purified Flavonoid Fraction for the Treatment of Post-Thrombotic Syndrome: protocol of a randomised controlled trial.

BMJ open·2021
Same author

Measuring functional limitations after venous thromboembolism: Optimization of the Post-VTE Functional Status (PVFS) Scale.

Thrombosis research·2020
Same author

Determining the minimal clinically important difference for the PEmbQoL questionnaire, a measure of pulmonary embolism-specific quality of life.

Journal of thrombosis and haemostasis : JTH·2018
Same author

Adherence to, and outcomes of, a galactomannan screening protocol in high-risk hematology patients.

Current oncology (Toronto, Ont.)·2018
Same journal

The Natural Mutation Arg221aTrp in Human α-Thrombin Abrogates Physiological Na<sup>+</sup> Binding and Preferentially Hinders the Protease Anticoagulant Functions.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

A historical review of the biological, semantic and clinical aspects of aspirin resistance.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

Association between Thrombus Neutrophil Extracellular Traps Content and Ischemic Stroke Recurrence.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

Peptide-Mediated Inhibition of Surface-Initiated Thrombogenesis.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

Growth differentiation factor-15 and bleeding risk in patients with venous thromboembolism.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

Physiological Anticoagulant Deficiencies: Pathogenesis, Diagnosis, and Clinical Implications.

Journal of thrombosis and haemostasis : JTH·2026
See all related articles

Long-term use of dalteparin, a low-molecular-weight heparin, during pregnancy does not significantly decrease bone mineral density (BMD). This study found no difference in BMD between pregnant women receiving dalteparin and controls, ensuring safety for bone health.

Area of Science:

  • Obstetrics and Gynecology
  • Pharmacology
  • Bone Metabolism

Background:

  • The impact of long-term prophylactic low-molecular-weight heparin (LMWH) on bone mineral density (BMD) during pregnancy remains unclear.
  • Investigating potential risks associated with LMWH use in obstetric patients is crucial for patient safety.

Purpose of the Study:

  • To evaluate the effect of long-term prophylactic dalteparin administration during pregnancy on maternal bone mineral density.
  • To determine if antepartum dalteparin prophylaxis influences BMD at six weeks postpartum.

Main Methods:

  • A substudy of a multicenter randomized trial involving thrombophilic pregnant women.
  • Participants were randomized to receive either daily dalteparin prophylaxis or a control regimen.
  • Primary outcome measured was absolute spine BMD at six weeks postpartum.

Related Experiment Videos

Main Results:

  • No significant difference in mean BMD was observed between the dalteparin intervention group (1.11 g cm(-2)) and the control group (1.14 g cm(-2)).
  • T-scores also showed no significant difference, with a confidence interval that excluded a clinically significant increase in fracture risk.
  • The study analyzed data from 62 eligible patients, with 33 in the intervention group and 29 in the control group.

Conclusions:

  • Long-term prophylactic use of dalteparin in pregnancy is not associated with a significant decrease in bone mineral density.
  • The findings suggest that dalteparin can be safely used for prophylaxis in pregnant women without compromising bone health.